One study concluded that the drug “does not act as a sport performance enhancing agent as raised by popular beliefs.”
It added, “Thus, cannabis consumption prior to exercise should be avoided in order to maximize performance in sports.”
A spokesman for WADA, Jon Fitzgerald, stated that WADA “consults with all stakeholders in relation to substances or methods that perhaps should be added or removed,” and he added that “throughout this time, the U.S. has been consistent in its strongly held position that WADA should keep cannabis on the List.”
Mr. Fitzgerald stated that the WADA authors “stand by” the 2011 scientific analysis, printed within the journal Sports Medicine, that appears expansively on the results of marijuana use on athletes. One part is dedicated to the drug’s potential to boost efficiency and attracts on a handful of earlier scientific research to help that risk.
Experts say the WADA evaluation goes past what the sooner papers truly said.
In one instance, the 2011 evaluation misstates the place expressed by a scientist named Jon Wagner in his 1989 paper titled “Abuse of Drugs Used to Enhance Athletic Performance.” The WADA paper asserts that Dr. Wagner “described cannabis as ergogenic,” that means performance-enhancing. Dr. Wagner, a former assistant professor on the University of Nebraska who now works within the biotech business, disagreed.
“I didn’t write that,” Dr. Wagner stated in an interview. In the paper, he wrote that marijuana doesn’t enhance “vital capacity” or grip power and that if marijuana helped in any respect, it will be by serving to an athlete loosen up. In an interview, he stated he had taken that final thought from anecdotal conversations with tennis gamers.
“That’s just it,” Dr. Wagner stated. “People just talking.”
“That was like a throwaway line,” he added. “I didn’t imagine it would have an impact in the world of Olympics.”